CTOs on the Move

Rigel Pharmaceuticals

www.rigel.com

 
Rigel Pharmaceuticals, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.rigel.com
  • 1180 Veterans Blvd
    South San Francisco, CA USA 94080
  • Phone: 650.624.1100

Executives

Name Title Contact Details

Similar Companies

Quintiles

Quintiles helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.”

Medicure

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.

C16 Biosciences

C16 was founded with the objective of creating a sustainable, environmentally friendly alternative to conflict palm oil. By offering producers, refiners, traders and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability efforts, our aim is to reduce the environmental footprint of palm oil production and protect precious natural land, wildlife and resources in the process.

World Views Spatial Technologi

World Views Spatial Technologi is a Barrington, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.